CDKN2A deletion in p16‐negative/ HPV ‐positive head and neck squamous cell carcinoma: Highlighting the molecular basis behind the limitation of relying on p16 immunohistochemistry as a surrogate marker for HPV involvement
Open Access
- 9 October 2025
- journal article
- Published by Wiley in Histopathology
- Vol. 88 (3) , 664-672
Abstract
Aims: Immunohistochemistry (IHC) for p16 is widely used as a surrogate marker for HPV involvement in oropharyngeal squamous cell carcinoma (OPSCC), among other tumours. Confirming HPV status in OPSCC is critical, as HPV‐positive tumours have better overall survival and may require de‐escalated therapy compared to HPV‐independent OPSCC in the future. However, discordance exists between p16 and HPV, and direct HPV testing is occasionally required to ensure an accurate diagnosis. The aim of this study is to highlight the genomic basis behind the limitation of relying on p16 IHC as a surrogate marker for HPV involvement. Methods and Results: Through a multi‐institutional collaboration, this case series compiled four patients with a ‘false’ negative p16 staining pattern in HPV‐positive non‐keratinizing head and neck squamous cell carcinoma. All cases demonstrated minimal to no p16 IHC staining and were positive for HPV by direct RNA in situ hybridization. Through CDKN2A fluorescence in situ hybridization testing, three patients demonstrated a homozygous deletion of CDKN2A and one demonstrated a heterozygous deletion. Conclusions: This series highlights the genomic basis for the ‘false’ negative p16 results, raising awareness of a significant diagnostic pitfall while emphasizing the importance of careful consideration of clinicopathologic parameters in the clinical workup of these cases.Keywords
This publication has 27 references indexed in Scilit:
- Uncommon and Challenging Phenotypes of High-Risk Human Papillomavirus-Associated Head and Neck Carcinomas Revealed by High-Throughput StudiesHead and Neck Pathology, 2024
- Abnormal p53 Immunohistochemical Patterns Are Associated with Regional Lymph Node Metastasis in Oral Cavity Squamous Cell Carcinoma at Time of SurgeryLaboratory Investigation, 2024
- RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell CarcinomaHead and Neck Pathology, 2021
- Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillanceOral Oncology, 2021
- Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta‐analysisInternational Journal of Cancer, 2016
- Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trialsHead & Neck, 2013
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialThe Lancet Oncology, 2013
- Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancerInternational Journal of Cancer, 2007
- Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteriInternational Journal of Cancer, 2001
- Expression Status of p16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital LesionsThe American Journal of Pathology, 1998